- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED May 30, 2023
Companies with a Value score of at least 3, ordered by Value score
424 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CDMOAvid Bioservices | US$15.02 | -2.8% | 12.3% | US$939.5m | US$22.25 | PE8.1x | E-13.6% | n/a | ||
| COLLCollegium Pharmaceutical | US$21.80 | -6.2% | 39.6% | US$754.2m | US$34.60 | PS1.4x | E25.3% | n/a | ||
| PBHPrestige Consumer Healthcare | US$58.00 | -3.9% | 3.9% | US$2.9b | US$72.20 | PS2.6x | E94.8% | n/a | ||
| PRTKParatek Pharmaceuticals | US$1.55 | -17.6% | -18.0% | US$88.8m | US$5.33 | PE-1.3x | E73.9% | n/a | ||
| ASRTAssertio Holdings | US$6.46 | -2.1% | 114.6% | US$359.6m | US$9.75 | PE3.7x | E6.8% | n/a | ||
| HEXOHEXO | CA$1.01 | -19.8% | -71.4% | CA$59.0m | CA$1.24 | PB0.2x | E57.8% | n/a | ||
| BTMDbiote | US$5.56 | 3.0% | -14.5% | US$102.9m | US$11.33 | PE-6x | E161.7% | n/a | ||
| PRGOPerrigo | US$31.60 | -4.5% | -20.7% | US$4.3b | US$48.00 | PB0.9x | E102.7% | 3.5% | ||
| AMRXAmneal Pharmaceuticals | US$2.39 | 6.2% | -34.2% | US$711.8m | US$3.50 | PB1.2x | S3.2% | 0% | ||
| SHCSotera Health | US$14.04 | -3.6% | -34.1% | US$4.0b | US$18.50 | PS4x | E57.3% | n/a | ||
| ALKSAlkermes | US$29.18 | -2.0% | -2.2% | US$4.8b | US$35.11 | PS4.3x | E60.5% | n/a | ||
| EAPI.FEuroapi | €11.10 | -1.9% | -21.8% | €962.1m | €16.20 | PB0.9x | E38.9% | n/a | ||
| GRFSGrifols | €8.61 | -1.5% | -33.2% | €6.8b | €13.28 | PE163.6x | E33.8% | 0% | ||
| CURL.FCuraleaf Holdings | CA$2.90 | 1.0% | -53.2% | CA$2.8b | CA$7.53 | PS1.5x | E61.1% | n/a | ||
| OGNOrganon | US$19.27 | -6.6% | -49.2% | US$4.9b | US$30.78 | PE6.6x | E13.2% | 5.8% | ||
| GTHXG1 Therapeutics | US$2.65 | -8.6% | -45.5% | US$136.9m | US$11.17 | PS2.4x | E49.9% | n/a | ||
| HITIHigh Tide | CA$1.27 | -7.3% | -54.3% | CA$128.3m | CA$5.05 | PB0.8x | E125.3% | n/a | ||
| NDVA.FIndiva | CA$0.035 | -12.4% | -79.5% | CA$7.4m | n/a | PE-0.7x | S12.2% | n/a | ||
| ADMAADMA Biologics | US$4.04 | -0.5% | 97.1% | US$898.0m | US$5.13 | PS4.9x | E61.7% | n/a | ||
| URGNUroGen Pharma | US$9.52 | -16.7% | 78.9% | US$223.3m | US$23.00 | PS3.3x | E64.0% | n/a | ||
| EGRXEagle Pharmaceuticals | US$20.46 | -2.5% | -56.2% | US$267.8m | US$29.50 | PS1x | E31.8% | n/a | ||
| GTBI.FGreen Thumb Industries | CA$7.72 | 4.2% | -31.1% | CA$2.5b | CA$17.52 | PS1.8x | E49.0% | n/a | ||
| SNCEScience 37 Holdings | US$0.22 | -25.4% | -94.3% | US$25.7m | US$1.81 | PB0.3x | E44.4% | n/a | ||
| OPTNOptiNose | US$1.27 | -14.2% | -38.2% | US$142.2m | US$4.00 | PS1.9x | E69.8% | n/a |